Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomaterials Applications
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Miyamoto, Y.
Right arrow Articles by Kawashima, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyamoto, Y.
Right arrow Articles by Kawashima, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Deleterious Effects of Complement Activation on the Lungs during Extracorporeal Circulation and Its Inhibition by FUT-175

Yuji Miyamoto, M.D.

The First Department of Surgery Osaka University Medical School 1-1-50 Fukushima Osaka, Japan 553

Hikaru Matsuda, M.D.

The First Department of Surgery Osaka University Medical School 1-1-50 Fukushima Osaka, Japan 553

Yasunaru Kawashima, M.D.

The First Department of Surgery Osaka University Medical School 1-1-50 Fukushima Osaka, Japan 553

The purpose of this paper is to review the deleterious effects of complement activation during extracorporeal circulation on the lungs and to discuss the feasibility of FUT-175, a new synthetic protease inhibitor, as a com plement activation inhibitor. Complement activation causes leukocyte ag gregation and aggregated leukocytes behave as microemboli in the pulmonary vessels. Anaphylatoxins produced by complement activation have potent vaso active properties and many chemical mediators are also released from leuko cytes. FUT-175 might be effective to inhibit complement activation during car diopulmonary bypass (CPB). Although deleterious effects of CPB on the lungs are multifactorial, we hypothesize that complement activation may play a ma jor role in lung injury during CPB.

Key Words: complement activation • cardiopulmonary bypass • complement inhibitor • FUT-175 • leukosequestration.

Journal of Biomaterials Applications, Vol. 4, No. 1, 56-68 (1989)
DOI: 10.1177/088532828900400104
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Finn, B. P. Morgan, N. Rebuck, N. Klein, C. A. Rogers, M. Hibbs, M. Elliott, D. F. Shore, T. W. Evans, S. Strobel, et al.
EFFECTS OF INHIBITION OF COMPLEMENT ACTIVATION USING RECOMBINANT SOLUBLE COMPLEMENT RECEPTOR 1 ON NEUTROPHIL CD11B/CD18 AND L-SELECTIN EXPRESSION AND RELEASE OF INTERLEUKIN-8 AND ELASTASE IN SIMULATED CARDIOPULMONARY BYPASS
J. Thorac. Cardiovasc. Surg., February 1, 1996; 111(2): 451 - 459.
[Abstract] [Full Text]